Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19293119 | 0.89 | — | — | |
| SCHEMBL25062317 | 0.78 | LMNA (0.42) | — | |
| SCHEMBL20964320 | 0.77 | — | — | |
| SCHEMBL22375459 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL28331770 | 0.75 | SOAT1 (0.34) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL8965 | 0.74 | SOAT1 (0.37) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL14321929 | 0.72 | ALDH1A1 (0.45) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL28000197 | 0.72 | KMT2A (0.35) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL232206 | 0.72 | KDM4E (0.36) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL561987 | 0.70 | KDM4E (0.35) | MEN1FAAHTP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220476-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200123100-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220476-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | MEN1 3647/4885FAAH 3137/4885TP53 115/4885 |
| US-20200123100-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | MEN1 3647/4885FAAH 3137/4885TP53 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.